COMP <GO>
CRL vs UNH // FORWARD P/E MULTIPLE
Charles River Laboratories International Inc. (NYSE) VS. UnitedHealth Group Incorporated (NYSE) • 15-METRIC TALLY: CRL 3
— UNH 12
▲ FORWARD P/E MULTIPLE LEADER: UNH
LAST: $359.41 (-4.44%) • MKT CAP: $17.95B
forward-pe
23.0x
LAST: $406.97 (-0.96%) • MKT CAP: $364.66B
forward-pe
17.1x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CRL VS. UNH)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | CRL | UNH | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 41.00% | 88.57% | -47.57 | UNH | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 0.40% | 11.47% | -11.07 | UNH | /roic <GO> |
| EV/EBITDA & P/E Valuation | 95.0x | 16.4x | +78.55 | UNH | /valuation <GO> |
| Free Cash Flow Yield | 3.10% | 6.48% | -3.38 | UNH | /fcf-yield <GO> |
| Operating Margin | 0.60% | 4.82% | -4.22 | UNH | /operating-margins <GO> |
| Net Profit Margin | -3.60% | 3.14% | -6.74 | UNH | /net-margins <GO> |
| Revenue Growth (YoY) | -0.90% | 6.46% | -7.36 | UNH | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.28% | -2.28 | UNH | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 3.65 | 3.12 | +0.53 | CRL | /balance-sheet <GO> |
| Piotroski F-Score Quality | 6/9 | 7/9 | -1.00 | UNH | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.40% | 6.74% | +0.66 | UNH | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 68.0 | 56.0 | +12.00 | CRL | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.15 | 0.33 | +0.82 | CRL | /macro-sensitivity <GO> |
| Forward P/E Multiple ACTIVE | 23.0x | 17.1x | +5.91 | UNH | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $17.95B | $364.66B | -$346.70B | UNH | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | CRL REV | UNH REV | CRL GROSS % | UNH GROSS % | CRL FCF | UNH FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $4.02B | $447.57B | 44.0% | 88.7% | $557.0M | $16.07B |
| FY 2024 | $4.05B | $400.28B | 44.0% | 88.3% | $552.3M | $20.70B |
| FY 2023 | $4.13B | $371.62B | 44.0% | 89.6% | $498.1M | $25.68B |
| FY 2022 | — | $324.16B | — | 89.6% | — | $23.40B |
| FY 2021 | — | $287.60B | — | 89.2% | — | $19.89B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CRL // BETA 1.15
UNH // BETA 0.33